The Effects of Preoperative Bevacizumab on Perioperative Complications
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE2
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
- Status
- RECRUITING
- Phase
- PHASE3
Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB
- Status
- RECRUITING
- Phase
- PHASE3
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- Status
- UNKNOWN
- Phase
- PHASE2
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
- Status
- TERMINATED
- Phase
- PHASE3
Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection
- Status
- UNKNOWN
- Phase
- PHASE3
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
- Status
- TERMINATED
- Phase
- PHASE2
Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
- Status
- UNKNOWN
- Phase
- PHASE3
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE2